Stealth BioTherapeutics

Barth Syndrome Awareness Day is celebrated around the world on April 5th to bring together all members of this ultra-rare disease community! Stealth is proud to work with such a resilient and steadfast group of individuals who continue to increase awareness of Barth syndrome.   Learn more about #BarthSyndromeAwarenessDay and how you can get involved here: http://bit.ly/3zzTjfm 

Attending the Informa Connect #RareDiseaseSummit in Philadelphia today? Be sure to check out Stealth's CEO, Reenie McCarthy, this afternoon as she presents at the pioneering perspectives spotlight session. Learn more here: https://bit.ly/3FKe6TC

Stealth is pleased to announce that 50% enrollment has been met in the ReNEW clinical trial evaluating patients with dry age-related macular degeneration! Thank you to all the ReNEW investigators and staff for your steadfast efforts in reaching this important milestone. Read the full press release here: https://bit.ly/41SDopY A special thank you to our ReNEW Trial Scientific Review Committee: Charles Wykoff (Chair), Carl Regillo and Michael Singer. Additional gratitude to our Scientific Advisory Board members; Charles Wykoff, David Brown, David Boyer, MD, Arshad M. Khanani, David Lally, Justis Ehlers, Peter Kaiser, and Jeff Heier for your trial design expertise and guidance as we aim to bring novel therapies to patients living with this devastating disease. #DryAMD https://bit.ly/41SDopY

Today is Rare Disease Day!! At Stealth, our mission is to lead the development of mitochondrial medicine to improve the lives of patients living with ultra-rare and rare diseases. Join us in raising awareness for the 300 million people living with a rare disease all around the world. Get involved at: https://lnkd.in/dgtircHT   #BarthSyndrome #PrimaryMiotchondrialMyopathy #FriedreichsAtaxia

Dry age-related macular degeneration (dAMD) is a leading cause of blindness impacting more than five million people in the United States alone, which can severely impair visual function, independence, and quality of life. At Stealth, we are studying the role of mitochondria in certain retinal diseases such as #DryAMD. Check out this video to learn more: https://lnkd.in/ehNgMupU   #EyesonMito #AMDAwarenessMonth 

People with dry age-related macular degeneration (dAMD) experience declining visual function, including blurred vision and difficulty seeing details particularly in low light. Dry AMD can progress to geographic atrophy, leading to irreversible central vision loss. At Stealth, we are conducting a clinical study for a treatment in dry AMD. Learn more at: https://lnkd.in/ejhBunD9   #EyesOnMito #AMDAwarenessMonth2025 

Happening today the Bascom Palmer Eye Institute 2025 Angiogenesis, Exudation, and Degeneration Virtual Meeting, we are excited to share new analyses from our Phase 2 ReCLAIM-2 trial in dry age-related macular degeneration (dAMD). #dryAMD Full program: https://lnkd.in/ePtCT-_C  

February is AMD Awareness Month! Did you know nearly 20 million Americans aged 40+ have been diagnosed with some form of macular degeneration? Follow along each week with The American Macular Degeneration Foundation this month to learn about early detection and risk reduction, impact on daily living, advocacy, and how you can take action!  #AMDAwarenessMonth2025 

The 2025 Mito Town Meeting agenda is live on our website! Check it out to see who will be presenting at the meeting and get a sneak peek for what we have in store for the mito community next year. Thank you to all of the wonderful organizations who are joining us at the 2025 Town Meeting! https://buff.ly/3Dmerec

In this holiday season, we cherish the connections we've made, the milestones we've achieved together, and the excitement of what is yet to come. May your holidays be filled with joy, and the New Year bring opportunities and continued progress. Happy Holidays and a Happy New Year from the entire Stealth team! 🎉